Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

viral test

  • Home
  •  
  • viral test



  • Most Read
  • Latest Comments
  • False positives: Lumos shares slaughtered as FDA knocks back application for viral infection test kits
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • False positives: Lumos shares slaughtered as FDA knocks back application for viral infection test kits
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • False positives: Lumos shares slaughtered as FDA knocks back application for viral infection test kits
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • False positives: Lumos shares slaughtered as FDA knocks back application for viral infection test kits
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • False positives: Lumos shares slaughtered as FDA knocks back application for viral infection test kits
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Lumos Diagnostics expands FebriDx distribution to Belgium
    Lumos Diagnostics expands FebriDx distribution to Belgium
    • News

  • Lumos completes phase 1 of developing premature birth detection test
    Lumos completes phase 1 of developing premature birth detection test
    • News

  • Mesoblast receives FDA support for accelerated approval pathway for heart failure treatment
    Mesoblast receives FDA support for accelerated approval pathway for heart failure treatment
    • News

  • As cash dwindles, Advanced Health Intelligence lists collabs and partnerships to turn things around
    As cash dwindles, Advanced Health Intelligence lists collabs and partnerships to turn things around
    • News

  • Lumos gets FDA approval for its bacteria detecting test, finally moves past its RAT test days
    Lumos gets FDA approval for its bacteria detecting test, finally moves past its RAT test days
    • News

  • False positives: Lumos shares slaughtered as FDA knocks back application for viral infection test kits
    • News

    False positives: Lumos shares slaughtered as FDA knocks back application for viral infection test kits

    While small cap shareholders have become accustomed to major share price gains once a medtech or biotech receives FDA approval to commercialise their products, it’s not all sunshine and rainbows on the FDA horizon as Lumos Diagnostics (ASX: LDX) has found, following the rejection of their FebriDx test kits.  As a rapid diagnostic test that

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.